AstraZeneca fends off lawsuit over alleged Soliris drug monopoly

By Reuters News

By Blake Brittain

- AstraZeneca's AZN.L Alexion Pharmaceuticals on Monday defeated a proposed class-action lawsuit in Massachusetts federal court that had accused it of misusing its patents to maintain a monopoly on its blockbuster blood-disease drug Soliris.

US District Judge Brian Murphy determined that Alexion was immune from the claims brought by health plan EmblemHealth on behalf of US Soliris purchasers under a doctrine that generally protects companies from antitrust liability for enforcing their intellectual property rights.

Spokespeople for EmblemHealth and AstraZeneca did not immediately respond to requests for comment on the decision.

AstraZeneca earned more than $1.8 billion in revenue from sales of Soliris last year, according to a company report. The drug is used to treat rare blood disorders.

EmblemHealth said in the complaint that the company wrongly obtained new patents to block biosimilar versions of Soliris for four years after its patents on the drug had expired.

Biosimilars are biologic drugs based on existing medicines for which the patents have expired. Like generics, they are usually sold at much cheaper ​prices than patented drugs.

The health plan stated that Alexion misled the US Patent and Trademark Office to get the patents and misused them to "extract settlements" from competitors and delay their biosimilars until March 2025 at the earliest.

The lawsuit said the alleged scheme violated US antitrust law and caused overpayments for Soliris estimated to exceed $2 billion.

Murphy on Monday agreed with Alexion that it was immune from the lawsuit. The judge rejected EmblemHealth's argument that the immunity doctrine did not apply because Alexion had allegedly brought "sham" litigation to enforce the patents.

The case is EmblemHealth Inc v. Alexion Pharmaceuticals Inc, US District Court for the District of Massachusetts, No. 1:25-cv-10985.

For EmblemHealth: Thomas Sobol of Hagens Berman Sobol Shapiro

For AstraZeneca: Ashley Bass of Covington & Burling

Read more:

AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.